2. 诱导疾病模型产品 Vitamin D Related/Nuclear Receptor Metabolic Enzyme/Protease Cell Cycle/DNA Damage Autophagy Apoptosis
  3. 遗传工程疾病模型 Estrogen Receptor/ERR HSP Autophagy Apoptosis
  4. Tamoxifen

Tamoxifen  (Synonyms: 他莫昔芬; ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen)

目录号: HY-13757A
一键复制产品信息 纯度: 99.96%
COA 产品使用指南 技术支持

Tamoxifen

Tamoxifen (ICI 47699) 是一种口服有效的，选择性雌激素受体 (estrogen receptor) 调节剂 (SERM)，可阻断乳腺细胞中的雌激素作用，并可激活其他细胞，如骨骼，肝脏和子宫细胞中的雌激素活性。Tamoxifen 是一种有效的 Hsp90 激活剂，可增强 Hsp90 分子伴侣 ATPase 的活性。Tamoxifen 还可以有效抑制传染性 EBOV Zaire 和 Marburg (MARV)，IC50 分别为 0.1 μM 和 1.8 μM。Tamoxifen 可以激活自噬 (autophagy)，诱导凋亡 (apoptosis)。Tamoxifen 还可以直接溶解于玉米油 (HY-Y1888) 后用于诱导 CreER 转基因小鼠的基因敲除 (Note: 避光配制，现配现用，不建议储存)。与 Tamoxifen Citrate (HY-13757) 相比，Tamoxifen 在玉米油中的溶解度更好。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

实验动物饲料定制

CAS No. : 10540-29-1

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥550
In-stock
100 mg ￥190
In-stock
100 mg * 2 ￥300
In-stock
100 mg * 5 ￥500
In-stock
100 mg * 10 ￥690
In-stock
5 g ￥2200
In-stock
10 g ￥3500
In-stock
50 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Tamoxifen:

Tamoxifen 相关抗体

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 213 篇科研文献

In Vivo Efficacy Study
Histological Imaging/Staining
IHC
WB
Cell Imaging/Staining

    Tamoxifen purchased from MCE. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7.  [Abstract]

    Peripheral blood chimerism (%Cd45.2) in mice engrafted with WT (Cd45.1) and Flt3Frt-ITD (Cd45.2) cells following treatment with Tamoxifen (4 mg/mouse; p.o.) (red) or control (black).

    Tamoxifen purchased from MCE. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7.  [Abstract]

    Flt3Frt-ITD (red), Dnmt3aLox-R878H-Flt3Frt-ITD (orange), and Npm1Frt-c-Flt3Frt-ITD (green) bone marrow was transplanted into lethally irradiated hosts. Kaplan-Meier survival plot following TAM (4 mg/mouse; p.o.).

    Tamoxifen purchased from MCE. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7.  [Abstract]

    Bone marrow H&E from either control mice or after 7 days of TAM (4 mg/mouse; p.o.).

    Tamoxifen purchased from MCE. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7.  [Abstract]

    Immunohistochemical staining on bone marrow for Ki67 (left) and phopsho-ERK1/2 (right) for untreated (top) and 7-day TAM (4 mg/mouse; p.o.) treated (bottom) Npm1Lox-C-Flt3GL-ITD mice.

    Tamoxifen purchased from MCE. Usage Cited in: Nat Cell Biol. 2024 Dec;26(12):2099-2114.  [Abstract]

    Tamoxifen (2 mg/day; i.p.; for 5 consecutive days) can effectively induce the removal of NAT1 in various tissues, including muscle, white adipose tissue, pancreas, and liver, in adult Nat1fl/fl;UBCcreERT2/+ mice and in Nat1fl/fl;UBCcreERT2/+;Ripk1D138N/D138N mice carrying a RIPK1 allele with an inactivation mutation.

    Tamoxifen purchased from MCE. Usage Cited in: Cancer Res. 2024 Nov 15;84(22):3728-3742.  [Abstract]

    Schematic image of selective YAP1 depletion model on Cd248-CreERT2; Yap1flox/flox mice by using Tamoxifen (120 mg/kg/day; i.p. for 5 d).

    Tamoxifen purchased from MCE. Usage Cited in: Redox Biol. 2022 Nov:57:102509.

    Expression of TFRC in primary fibroblasts from TFRCflox/flox and TFRC−/− mice was assessed by western blot after 5 days of Tamoxifen intraperitoneal injection and 7 days of waiting.

    Tamoxifen purchased from MCE. Usage Cited in: Theranostics. 2020 Aug 29;10(24):10874-10891.  [Abstract]

    Representative fields, intracellular TG contents and secreted TG of female C57BL/6 mice hepatocytes treated with C29, Tamoxifen (20 μM; 36 h), Toremifene and 4-OHT. LDs were labeled with Nile Red (red).

    Tamoxifen purchased from MCE. Usage Cited in: Theranostics. 2020 Aug 29;10(24):10874-10891.  [Abstract]

    Representative images of liver tissue (top), sections stained with Oil Red O (bottom) and liver TG levels from Ad-ERRα or Ad-Ctrl-injected female mice treated with TMX (100 mg/kg; p.o. for 5 days).

    Tamoxifen purchased from MCE. Usage Cited in: Clin Transl Med. 2020 Jan;10(1):137-150.  [Abstract]

    Different transmission of MAPK8/FoxO signaling pathway in breast cancer cells (MCF-7, T47D, ZR-75, and MDA-MB-231) and liver cells (LO2) exposed to TAM (Tamoxifen).

    Tamoxifen purchased from MCE. Usage Cited in: Cell Commun Signal. 2019 May 23;17(1):50.  [Abstract]

    Tamoxifen inhibits the growth and metastasis of prostate tumors in vivo. Western blot analysis of the indicated proteins in prostate primary tumors tissues.

    查看 Estrogen Receptor/ERR 亚型特异性产品:

    查看所有亚型
    Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

    查看 HSP 亚型特异性产品:

    查看所有亚型
    HSP40 HSP70 HSP90 HSP105 HSF1 HSP HSPA5

    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells[1][2][3]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively[5]. Tamoxifen activates autophagy and induces apoptosis[4]. Tamoxifen can also be dissolved in corn oil (HY-Y1888) for use in inducing gene knockout in CreER transgenic mice. (Note: The solution should be prepared protected from light, freshly made before use, and storage is not recommended.). Tamoxifen has better solubility in corn oil compared to Tamoxifen Citrate (HY-13757)[6].

    IC50 & Target[1][4]

    Estrogen receptor

     

    HSP90

     

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    518A2 IC50
    7.62 μM
    Compound: 2
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    		[PMID: 22749392]
    A-431 ED50
    7 μg/mL
    Compound: TAM
    Cytotoxicity against human A431 cells
    Cytotoxicity against human A431 cells
    		[PMID: 16942038]
    A-431 IC50
    > 100 μM
    Compound: Tamoxifen
    Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
    Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
    		[PMID: 29605808]
    A2058 EC50
    12.5 μM
    Compound: TAM
    Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay
    Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay
    		[PMID: 31099568]
    A2780 GI50
    30.3 μM
    Compound: 1
    Cytotoxicity against human A2780 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    Cytotoxicity against human A2780 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    		[PMID: 27128175]
    A2780 IC50
    7.77 μM
    Compound: 2
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    		[PMID: 22749392]
    A549 GI50
    24.4 μM
    Compound: Tamoxifen
    Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay
    Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay
    		[PMID: 26163220]
    A549 IC50
    1.86 μg/mL
    Compound: Tomoxifen
    Cytotoxicity against human A549 cells by alamar blue assay
    Cytotoxicity against human A549 cells by alamar blue assay
    		[PMID: 11720540]
    A549 IC50
    10.08 μM
    Compound: Tamoxifen
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    		[PMID: 31884407]
    A549 IC50
    10.87 μM
    Compound: Tamoxifen
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		[PMID: 31546197]
    A549 IC50
    12 μM
    Compound: TAM
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 23287057]
    A549 IC50
    17.3 μM
    Compound: Tamoxifen
    Anticancer activity against human A549 cells measured after 48 hrs by SRB assay
    Anticancer activity against human A549 cells measured after 48 hrs by SRB assay
    		[PMID: 27671497]
    A549 IC50
    17.3 μM
    Compound: Tamoxifen
    Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
    Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
    		[PMID: 29605808]
    A549 IC50
    8.4 μM
    Compound: Tamoxifen
    Cytotoxicity against human A549 cells assessed as cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability by MTT assay
    		[PMID: 26079090]
    A549 IC50
    9.66 μM
    Compound: 2
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    		[PMID: 22749392]
    Astrocyte IC50
    > 10 μM
    Compound: Tamoxifen
    Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method
    Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method
    		[PMID: 26355532]
    B16-F10 IC50
    64.87 μM
    Compound: Tam
    Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay
    Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay
    		[PMID: 25222876]
    CHO IC50
    > 100 μM
    Compound: Tam
    Antiproliferative activity against CHO cells after 2 days by MTT assay
    Antiproliferative activity against CHO cells after 2 days by MTT assay
    		[PMID: 25222876]
    Caco-2 EC50
    56.5 μM
    Compound: Tamoxifen
    Inhibition of P-glycoprotein-mediated [3H]vinblastine transport in human Caco-2 cells
    Inhibition of P-glycoprotein-mediated [3H]vinblastine transport in human Caco-2 cells
    		[PMID: 18524592]
    Caco-2 IC50
    29 μM
    Compound: Tamoxifen
    TP_TRANSPORTER: transepithelial transport of Rhodamine 123 (basal to apical) in Caco-2 cells
    TP_TRANSPORTER: transepithelial transport of Rhodamine 123 (basal to apical) in Caco-2 cells
    		[PMID: 15386482]
    Cancer cell lines IC50
    10.6 μM
    Compound: Tamoxifen
    Antiproliferative activity in MDA-MB 231 human breast cancer cells
    Antiproliferative activity in MDA-MB 231 human breast cancer cells
    		[PMID: 15658875]
    DLD-1 IC50
    11.06 μM
    Compound: Tamoxifen
    Anticancer activity against human DLD1 cells measured after 48 hrs by SRB assay
    Anticancer activity against human DLD1 cells measured after 48 hrs by SRB assay
    		[PMID: 27671497]
    DLD-1 IC50
    16.3 μM
    Compound: Tamoxifen
    Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
    Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
    		[PMID: 29605808]
    DLD-1 IC50
    4.78 μM
    Compound: 2
    Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
    Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
    		[PMID: 22749392]
    DU-145 GI50
    19.3 μM
    Compound: Tamoxifen
    Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay
    Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay
    		[PMID: 26163220]
    DU-145 GI50
    6.07 μM
    Compound: Tamoxifen
    Anticancer activity against human DU145 cells after 24 hrs by SRB assay
    Anticancer activity against human DU145 cells after 24 hrs by SRB assay
    		[PMID: 19733085]
    DU-145 IC50
    10.87 μM
    Compound: Tamoxifen
    Antiproliferative activity against human DU145 cells by MTT assay
    Antiproliferative activity against human DU145 cells by MTT assay
    		[PMID: 31546197]
    DU-145 IC50
    18.07 μM
    Compound: Tamoxifen
    Anticancer activity against human DU145 cells measured after 48 hrs by SRB assay
    Anticancer activity against human DU145 cells measured after 48 hrs by SRB assay
    		[PMID: 27671497]
    DU-145 IC50
    28.9 μM
    Compound: Tamoxifen
    Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23786452]
    DU-145 IC50
    5.5 μM
    Compound: TAM
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 23287057]
    EKVX GI50
    6.3 μM
    Compound: TAM
    Cytotoxicity against human EKVX cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human EKVX cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26896706]
    EL4 IC50
    535 nM
    Compound: 1a
    Inhibition of [3H]thymidine incorporation into EL4 cell proliferation
    Inhibition of [3H]thymidine incorporation into EL4 cell proliferation
    		[PMID: 1573630]
    FaDu IC50
    5.39 μM
    Compound: Tamoxifen
    Anticancer activity against human FADU cells measured after 48 hrs by SRB assay
    Anticancer activity against human FADU cells measured after 48 hrs by SRB assay
    		[PMID: 27671497]
    Fibroblast CC50
    11.1 μM
    Compound: Tamoxifen
    Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33373820]
    Fibroblast CC50
    12.7 μM
    Compound: Tamoxifen
    Cytotoxicity against human HSF cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
    Cytotoxicity against human HSF cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
    		[PMID: 33373820]
    Fibroblast IC50
    > 20 μM
    Compound: TAM
    Antiproliferative activity against mouse fibroblasts after 48 hrs by MTT assay
    Antiproliferative activity against mouse fibroblasts after 48 hrs by MTT assay
    		[PMID: 23287057]
    HCT-116 IC50
    45 μM
    Compound: Tamoxifen
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    		[PMID: 31884407]
    HCT-15 GI50
    3.16 μM
    Compound: TAM
    Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26896706]
    HEK-293T IC50
    0.039 μM
    Compound: Tamoxifen
    Antagonist activity at Gal4 DBD-fused human ERalpha LBD expressed in HEK293T cells assessed as inhibition of estradiol-induced transcriptional activation after 20 hrs by luciferase reporter gene assay
    Antagonist activity at Gal4 DBD-fused human ERalpha LBD expressed in HEK293T cells assessed as inhibition of estradiol-induced transcriptional activation after 20 hrs by luciferase reporter gene assay
    		[PMID: 23786452]
    HEK293 CC50
    13.1 μg/mL
    Compound: Tamoxifen
    Cytotoxicity against human HEK293 cells assessed as reduction in cell growth incubated for 20 hrs by resazurin dye-based fluorometric assay
    Cytotoxicity against human HEK293 cells assessed as reduction in cell growth incubated for 20 hrs by resazurin dye-based fluorometric assay
    		[PMID: 30831407]
    HEK293 CC50
    13.1 μg/mL
    Compound: Tamoxifen
    Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 20 hrs by resazurin dye-based fluorescence assay
    Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 20 hrs by resazurin dye-based fluorescence assay
    		[PMID: 30901686]
    HEK293 CC50
    13 μg/mL
    Compound: TAM
    Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis
    Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis
    		[PMID: 30316060]
    HEK293 CC50
    39.4 μM
    Compound: Tamoxifen
    Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis
    Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis
    		[PMID: 30322754]
    HEK293 CC50
    62 μM
    Compound: Tamoxifen
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay
    		[PMID: 28257200]
    HEK293 CC50
    9 μg/mL
    Compound: Tamoxifen
    Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay
    Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay
    		[PMID: 32619924]
    HEK293 CC50
    9 μg/mL
    Compound: Tamoxifen
    Cytotoxicity against HEK293 cells assessed as cell viability after 20 hrs by fluorescence assay
    Cytotoxicity against HEK293 cells assessed as cell viability after 20 hrs by fluorescence assay
    		[PMID: 33609657]
    HEK293 CC50
    9 μg/mL
    Compound: Tamoxifen
    Cytotoxicity against human HEK-293 cells incubated for 23 hrs by CO-ADD method
    Cytotoxicity against human HEK-293 cells incubated for 23 hrs by CO-ADD method
    		[PMID: 33738069]
    HEK293 IC50
    10 μM
    Compound: Tamoxifen
    Cytotoxicity against HEK293 cells after 24 hrs by MTT assay
    Cytotoxicity against HEK293 cells after 24 hrs by MTT assay
    		[PMID: 20605470]
    HEK293 IC50
    10 μM
    Compound: Tamoxifen
    Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
    		[PMID: 21871812]
    HEK293 IC50
    20.93 μM
    Compound: Tamoxifen
    Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
    Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
    		[PMID: 29054359]
    HEK293 IC50
    22.4 μM
    Compound: TAM
    Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 34153643]
    HEK293 IC50
    24 μM
    Compound: Tamoxifen
    Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay
    Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay
    		[PMID: 30975502]
    HEK293 IC50
    24 μM
    Compound: Tamoxifen
    Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 20 hrs by resazurin dye based assay
    Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 20 hrs by resazurin dye based assay
    		[PMID: 35477062]
    HEK293 IC50
    26 μM
    Compound: TAM
    Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
    		[PMID: 24457094]
    HEK293 IC50
    26.33 μM
    Compound: 1
    Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 35276362]
    HEK293 IC50
    50 μM
    Compound: Tamoxifen
    Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
    		[PMID: 24880230]
    HEK293 IC50
    > 50 μM
    Compound: Tamoxifen
    Cytotoxicity against HEK293 cells by MTT assay
    Cytotoxicity against HEK293 cells by MTT assay
    		[PMID: 31546197]
    HL-60 IC50
    14.3 μM
    Compound: Tamoxifen
    Cytotoxicity against human HL60 cells after 72 hrs by WST1 assay in presence of 20% FBS
    Cytotoxicity against human HL60 cells after 72 hrs by WST1 assay in presence of 20% FBS
    		[PMID: 22901895]
    HL-60 IC50
    5.9 μg/mL
    Compound: 1, Tamoxifen
    Growth inhibition of human HL60 cells after 4 hrs by MTT assay
    Growth inhibition of human HL60 cells after 4 hrs by MTT assay
    		[PMID: 17904372]
    HT-29 GI50
    9.5 μM
    Compound: Tamoxifen
    Growth inhibition of human HT-29 cells
    Growth inhibition of human HT-29 cells
    		[PMID: 23403084]
    HT-29 IC50
    1.86 μg/mL
    Compound: Tomoxifen
    Cytotoxicity against human HT-29 cells by alamar blue assay
    Cytotoxicity against human HT-29 cells by alamar blue assay
    		[PMID: 11720540]
    HT-29 IC50
    38.6 μM
    Compound: tamoxifen
    Cytotoxicity against human HT-29 cells after 24 hrs by CellTiter-BlueCell viability assay
    Cytotoxicity against human HT-29 cells after 24 hrs by CellTiter-BlueCell viability assay
    		[PMID: 20545334]
    HeLa GI50
    12 μM
    Compound: 1
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by trypan blue assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by trypan blue assay
    		[PMID: 27128175]
    HeLa GI50
    32.6 μM
    Compound: 1
    Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue assay
    Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue assay
    		[PMID: 23735829]
    HeLa IC50
    0.341 μM
    Compound: Tamoxifen
    Antagonist activity at full length ERalpha (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay
    Antagonist activity at full length ERalpha (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay
    		[PMID: 28882502]
    HeLa IC50
    0.73 μM
    Compound: Tamoxifen
    Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
    Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
    		[PMID: 29624387]
    HeLa IC50
    1.53 μM
    Compound: Tamoxifen
    Antagonist activity at full length ERbeta (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay
    Antagonist activity at full length ERbeta (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay
    		[PMID: 28882502]
    HeLa IC50
    10.87 μM
    Compound: Tamoxifen
    Antiproliferative activity against human HeLa cells by MTT assay
    Antiproliferative activity against human HeLa cells by MTT assay
    		[PMID: 31546197]
    HeLa IC50
    12.5 μM
    Compound: Tamoxifen
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    		[PMID: 20605470]
    HeLa IC50
    622 nM
    Compound: 6
    Inhibition of 17-beta-estradiol mediated luciferase transcription in HeLa cells expressing human estrogen receptor alpha; ERE assay
    Inhibition of 17-beta-estradiol mediated luciferase transcription in HeLa cells expressing human estrogen receptor alpha; ERE assay
    		[PMID: 15658851]
    HeLa IC50
    8.85 μM
    Compound: Tamoxifen
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 28838694]
    HeLa IC50
    > 1000 nM
    Compound: 6
    Inhibition of 17-beta-estradiol mediated luciferase transcription in HeLa cells expressing human estrogen receptor beta; ERE assay
    Inhibition of 17-beta-estradiol mediated luciferase transcription in HeLa cells expressing human estrogen receptor beta; ERE assay
    		[PMID: 15658851]
    HepG2 CC50
    24.7 μM
    Compound: Tamoxifen
    Cytotoxicity against human HepG2 cells after 24 hrs by resazurin dye-based fluorescence analysis
    Cytotoxicity against human HepG2 cells after 24 hrs by resazurin dye-based fluorescence analysis
    		[PMID: 30322754]
    HepG2 CC50
    6.15 μg/mL
    Compound: Tamoxifen
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 38784457]
    HepG2 CC50
    62 μM
    Compound: Tamoxifen
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay
    		[PMID: 28257200]
    HepG2 EC50
    35 μM
    Compound: Tamoxifen
    Cytotoxicity in human HepG2 cells assessed as induction of cell necrosis incubated for 4 hrs by LDH release assay
    Cytotoxicity in human HepG2 cells assessed as induction of cell necrosis incubated for 4 hrs by LDH release assay
    		[PMID: 27652492]
    HepG2 EC50
    35 μM
    Compound: Tamoxifen
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 4 hrs by CellTiter-Glo assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 4 hrs by CellTiter-Glo assay
    		[PMID: 27652492]
    HepG2 GI50
    21.7 μM
    Compound: Tamoxifen
    Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay
    Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay
    		[PMID: 26163220]
    HepG2 IC50
    11.7 μM
    Compound: Tamoxifen
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in DMEM/10% FBS supplemented with galactose by CellTiter-Glo luminescent assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in DMEM/10% FBS supplemented with galactose by CellTiter-Glo luminescent assay
    		[PMID: 37736177]
    HepG2 IC50
    11.72 μM
    Compound: Tamoxifen
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by Cell Titer Glo assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by Cell Titer Glo assay
    		[PMID: 39026652]
    HepG2 IC50
    12 μM
    Compound: Tamoxifen
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 30613327]
    HepG2 IC50
    19.6 μM
    Compound: Tamoxifen
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by cell-titer 96 aqueous one solution cell proliferation assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by cell-titer 96 aqueous one solution cell proliferation assay
    		[PMID: 34015704]
    HepG2 IC50
    23.4 μM
    Compound: Tamoxifen
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 32386856]
    HepG2 IC50
    23.4 μM
    Compound: Tamoxifen
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in DMEM/10% FBS supplemented with glucose by CellTiter-Glo luminescent assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in DMEM/10% FBS supplemented with glucose by CellTiter-Glo luminescent assay
    		[PMID: 37736177]
    HepG2 IC50
    23.4 μM
    Compound: tamoxifen
    Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-BlueCell viability assay
    Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-BlueCell viability assay
    		[PMID: 20545334]
    HepG2 IC50
    6.3 μM
    Compound: TAM
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 23287057]
    Hepatocyte EC50
    34.4 μM
    Compound: Tamoxifen
    Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay
    Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay
    		[PMID: 22531045]
    Hepatocyte EC50
    67.6 μM
    Compound: Tamoxifen
    Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by LDH release assay
    Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by LDH release assay
    		[PMID: 22531045]
    Hepatocyte EC50
    71.4 μM
    Compound: Tamoxifen
    Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay
    Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay
    		[PMID: 22531045]
    Hs-578T ED50
    7 μg/mL
    Compound: TAM
    Cytotoxicity against human HS 587-T cells lacking ER
    Cytotoxicity against human HS 587-T cells lacking ER
    		[PMID: 16942038]
    Ishikawa EC50
    33 nM
    Compound: 2
    Concentration of compound required to induce 50 % of the maximum stimulation of alkaline phosphatase activity in Ishikawa cells
    Concentration of compound required to induce 50 % of the maximum stimulation of alkaline phosphatase activity in Ishikawa cells
    		[PMID: 8201587]
    Ishikawa IC50
    0.42 μM
    Compound: tamoxifen
    Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 4 days by ELISA
    Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 4 days by ELISA
    		[PMID: 9784163]
    Ishikawa IC50
    14.58 μM
    Compound: Tamoxifen
    Antiproliferative activity against ER-positive human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against ER-positive human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 34509864]
    Ishikawa IC50
    16.47 μM
    Compound: Tamoxifen
    Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay
    Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay
    		[PMID: 28460819]
    Ishikawa IC50
    16.78 μM
    Compound: Tamoxifen
    Antiproliferative activity against human Ishikawa cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against human Ishikawa cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 34022716]
    Ishikawa IC50
    170 nM
    Compound: 1a
    Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 72 hrs
    Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 72 hrs
    		[PMID: 18835176]
    Ishikawa IC50
    20.65 μM
    Compound: Tamoxifen
    Cytotoxicity in human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity in human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 28942113]
    Ishikawa IC50
    22.5 μM
    Compound: Tamoxifen
    Antiproliferative activity against human Ishikawa cells expressing estrogen receptor after 48 hrs by MTT assay
    Antiproliferative activity against human Ishikawa cells expressing estrogen receptor after 48 hrs by MTT assay
    		[PMID: 21871812]
    Ishikawa IC50
    26.52 μM
    Compound: Tamoxifen
    Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay
    Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay
    		[PMID: 29587221]
    Ishikawa IC50
    6 μM
    Compound: Tamoxifen
    Antiproliferative activity against human Ishikawa cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human Ishikawa cells incubated for 48 hrs by MTT assay
    		[PMID: 27176944]
    Ishikawa IC50
    7.87 μg/mL
    Compound: Tamoxifen
    Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay
    Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay
    		[PMID: 28442256]
    J774.A1 CC50
    11.06 μM
    Compound: Tamoxifen
    Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability incubated for 24 hrs by neutral red uptake assay
    Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability incubated for 24 hrs by neutral red uptake assay
    		[PMID: 31376569]
    Jurkat IC50
    8.3 μM
    Compound: Tamoxifen
    Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay
    Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay
    		[PMID: 23792352]
    K562 GI50
    5.2 μM
    Compound: tamoxifen
    Antiproliferative activity against human K562 cells after 72 hrs
    Antiproliferative activity against human K562 cells after 72 hrs
    		[PMID: 25420175]
    KB ED50
    9 μg/mL
    Compound: TAM
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 16942038]
    L6 IC50
    4.9 μg/mL
    Compound: tamoxifen
    Cytotoxicity against rat L6 cells
    Cytotoxicity against rat L6 cells
    		[PMID: 19168363]
    Leukemia cell GI50
    2.08 μM
    Compound: TAM
    Antiproliferative activity against human leukemia cells
    Antiproliferative activity against human leukemia cells
    		[PMID: 32898794]
    M-HeLa IC50
    28 μM
    Compound: Tamoxifen
    Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method
    Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method
    		[PMID: 31610378]
    M-HeLa IC50
    28 μM
    Compound: Tamoxifen
    Antiproliferative activity against human M-HeLa cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay
    Antiproliferative activity against human M-HeLa cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay
    		[PMID: 31673312]
    M-HeLa IC50
    28 μM
    Compound: Tamoxifen
    Cytotoxicity against human M-HeLa cells
    Cytotoxicity against human M-HeLa cells
    		[PMID: 32386856]
    M-HeLa IC50
    28 μM
    Compound: Tmx
    Anticancer activity against human HelaM cells assessed as cell growth inhibition measured after 24 hrs by DAPI and propidium iodide staining based assay
    Anticancer activity against human HelaM cells assessed as cell growth inhibition measured after 24 hrs by DAPI and propidium iodide staining based assay
    		[PMID: 36481599]
    M21 GI50
    11 μM
    Compound: Tamoxifen
    Growth inhibition of human M21 cells
    Growth inhibition of human M21 cells
    		[PMID: 23403084]
    MCF-10A IC50
    14.267 μM
    Compound: 1; TMX
    Anticancer activity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by CVDK-8 method
    Anticancer activity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by CVDK-8 method
    		[PMID: 37484572]
    MCF-10A IC50
    15 μM
    Compound: 1; TMX
    Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell growth
    Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell growth
    		[PMID: 37484572]
    MCF-10A IC50
    26.8 μM
    Compound: TMX
    Cytotoxicity against human MCF-10A assessed as reduction in cell viability measured after 48 hrs by WST-1 assay
    Cytotoxicity against human MCF-10A assessed as reduction in cell viability measured after 48 hrs by WST-1 assay
    		[PMID: 38020071]
    MCF-10A IC50
    8.263 μM
    Compound: 1; TMX
    Anticancer activity against human MCF-10A cells assessed as inhibition of cell growth incubated for 48 hrs by CVDK-8 method
    Anticancer activity against human MCF-10A cells assessed as inhibition of cell growth incubated for 48 hrs by CVDK-8 method
    		[PMID: 37484572]
    MCF-10A IC50
    > 1000 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    		[PMID: 36603398]
    MCF-10A IC50
    > 1000 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    		[PMID: 36603398]
    MCF-10A IC50
    > 50 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF-10A cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF-10A cells after 48 hrs by MTT assay
    		[PMID: 33340662]
    MCF7 EC50
    0.11 nM
    Compound: TAM Z
    Effective dose for [3H]- estradiol against proliferation of MCF-7 cells
    Effective dose for [3H]- estradiol against proliferation of MCF-7 cells
    		[PMID: 2769681]
    MCF7 EC50
    10 nM
    Compound: 3 (Tamoxifen)
    Effective concentration against MCF-7 breast tumor cells using MCF-7 assay.
    Effective concentration against MCF-7 breast tumor cells using MCF-7 assay.
    		[PMID: 12825935]
    MCF7 EC50
    > 200 nM
    Compound: 2
    Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay
    Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay
    		[PMID: 34251202]
    MCF7 ED50
    5 μg/mL
    Compound: TAM
    Cytotoxicity against human MCF7 cells expressing ER
    Cytotoxicity against human MCF7 cells expressing ER
    		[PMID: 16942038]
    MCF7 ED50
    5 μg/mL
    Compound: TAM
    Cytotoxicity against human MCF7 cells expressing estrogen receptor after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells expressing estrogen receptor after 72 hrs by SRB assay
    		[PMID: 19425534]
    MCF7 GI50
    1.58 μM
    Compound: TAM
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26896706]
    MCF7 GI50
    11.2 μM
    Compound: Tamoxifen
    Growth inhibition of estrogen-dependent human MCF7 cells
    Growth inhibition of estrogen-dependent human MCF7 cells
    		[PMID: 23403084]
    MCF7 GI50
    12 μM
    Compound: 1
    Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue assay
    		[PMID: 23735829]
    MCF7 GI50
    6.5 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by trypan blue assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by trypan blue assay
    		[PMID: 27128175]
    MCF7 GI50
    6.8 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 120 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 120 hrs by MTT assay
    		[PMID: 28152429]
    MCF7 GI50
    8 μM
    Compound: Tamoxifen
    Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay
    Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay
    		[PMID: 26163220]
    MCF7 GI50
    < 10 μg/mL
    Compound: Tmx
    Growth inhibition of human MCF7 cells assessed as cell growth inhibition by SRB assay
    Growth inhibition of human MCF7 cells assessed as cell growth inhibition by SRB assay
    		[PMID: 36481599]
    MCF7 IC50
    0.027 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 22472045]
    MCF7 IC50
    0.14 μM
    Compound: tamoxifen (TAM)
    Anti-proliferative activity against estrogen-responsive human breast cancer cell line MCF-7 in the presence of ER at a 10e-4 uM concentration of estradiol
    Anti-proliferative activity against estrogen-responsive human breast cancer cell line MCF-7 in the presence of ER at a 10e-4 uM concentration of estradiol
    		[PMID: 8784443]
    MCF7 IC50
    0.15 μM
    Compound: Tamoxifen, ICI-46474
    Inhibition of estrogen receptor positive MCF-7 human breast cancer cell proliferation
    Inhibition of estrogen receptor positive MCF-7 human breast cancer cell proliferation
    		[PMID: 9357519]
    MCF7 IC50
    0.794 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells after 5 days
    Cytotoxicity against human MCF7 cells after 5 days
    		[PMID: 23864928]
    MCF7 IC50
    1 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells by MTT assay
    Antiproliferative activity against human MCF7 cells by MTT assay
    		[PMID: 20451380]
    MCF7 IC50
    1.31 μg/mL
    Compound: Tamoxifen
    Antiproliferative activity against human MCF-7 cells assessed as inhibition of colony formation measured after 3 weeks by crystal violet staining based soft agar colony formation assay
    Antiproliferative activity against human MCF-7 cells assessed as inhibition of colony formation measured after 3 weeks by crystal violet staining based soft agar colony formation assay
    		[PMID: 31884407]
    MCF7 IC50
    1.56 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells incubated for 5 days by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 5 days by MTT assay
    		[PMID: 38870830]
    MCF7 IC50
    1.82 μM
    Compound: TAMOX, TAM
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23123017]
    MCF7 IC50
    1.89 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 24721727]
    MCF7 IC50
    10 μM
    Compound: 1; TMX
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth
    		[PMID: 37484572]
    MCF7 IC50
    10 μM
    Compound: tamoxifene
    Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
    		[PMID: 19423356]
    MCF7 IC50
    10.2 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 36780831]
    MCF7 IC50
    10.74 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay
    		[PMID: 37146520]
    MCF7 IC50
    10.87 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells by MTT assay
    Antiproliferative activity against human MCF7 cells by MTT assay
    		[PMID: 31546197]
    MCF7 IC50
    10.9 μM
    Compound: Tamoxifen
    Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay
    Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay
    		[PMID: 19836230]
    MCF7 IC50
    10 μg/mL
    Compound: 125
    Antiproliferative activity against human MCF7 cells
    Antiproliferative activity against human MCF7 cells
    		10.1039/C2MD20089A
    MCF7 IC50
    11 μM
    Compound: Tamoxifen
    Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay
    Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay
    		[PMID: 12565971]
    MCF7 IC50
    11.1 μM
    Compound: Tamoxifen
    Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay
    Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay
    		[PMID: 19836230]
    MCF7 IC50
    11.28 μM
    Compound: 1a
    Antiproliferative activity against Human MCF-7 Breast cancer cell line in vitro.
    Antiproliferative activity against Human MCF-7 Breast cancer cell line in vitro.
    		[PMID: 11297454]
    MCF7 IC50
    11.35 μM
    Compound: Tamoxifen
    Antiproliferative activity against ER positive human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against ER positive human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 28460819]
    MCF7 IC50
    11.4 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells by WST-1 assay
    Cytotoxicity against human MCF7 cells by WST-1 assay
    		[PMID: 19836230]
    MCF7 IC50
    11.44 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 23022281]
    MCF7 IC50
    11.55 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    		[PMID: 31884407]
    MCF7 IC50
    11.8 μM
    Compound: Tamoxifen
    Anticancer activity against human MCF7 cells expressing estrogen receptor by MTT assay
    Anticancer activity against human MCF7 cells expressing estrogen receptor by MTT assay
    		[PMID: 20951035]
    MCF7 IC50
    12 μM
    Compound: tamoxifen
    Anticancer activity against estrogen-positive human MCF7 cells after 18 hrs by MTT assay
    Anticancer activity against estrogen-positive human MCF7 cells after 18 hrs by MTT assay
    		[PMID: 19446930]
    MCF7 IC50
    12.35 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 23830503]
    MCF7 IC50
    12.48 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
    		[PMID: 21871812]
    MCF7 IC50
    12.5 μM
    Compound: Tam
    Cytotoxicity against human MCF7 cells expressing ER after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells expressing ER after 48 hrs by MTT assay
    		10.1039/C4MD00289J
    MCF7 IC50
    12.6 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 38911170]
    MCF7 IC50
    13.45 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 23902804]
    MCF7 IC50
    13.7 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells
    Antiproliferative activity against human MCF7 cells
    		[PMID: 27155469]
    MCF7 IC50
    13.7 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells by MTT reduction assay
    Antiproliferative activity against human MCF7 cells by MTT reduction assay
    		[PMID: 33421712]
    MCF7 IC50
    14 μM
    Compound: 1
    In vitro cytotoxicity against hormone-responsive MCF-7 cell line.
    In vitro cytotoxicity against hormone-responsive MCF-7 cell line.
    		[PMID: 7830266]
    MCF7 IC50
    14.096 μM
    Compound: 1; TMX
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CVDK-8 method
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CVDK-8 method
    		[PMID: 37484572]
    MCF7 IC50
    14.35 μM
    Compound: Tamoxifen
    Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 28942113]
    MCF7 IC50
    15.2 μM
    Compound: 6
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 23880359]
    MCF7 IC50
    15.21 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 33340662]
    MCF7 IC50
    15.46 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 29587221]
    MCF7 IC50
    15.6 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23786452]
    MCF7 IC50
    16.7 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 30384047]
    MCF7 IC50
    17 μM
    Compound: Tamoxifen
    In vitro inhibition of estrogen receptor positive MCF-7 human mammary carcinoma cell proliferation
    In vitro inhibition of estrogen receptor positive MCF-7 human mammary carcinoma cell proliferation
    		10.1016/0960-894X(95)00381-3
    MCF7 IC50
    18.18 μM
    Compound: Tamoxifen
    Anticancer activity against human ER-positive MCF7 cells measured after 48 hrs by SRB assay
    Anticancer activity against human ER-positive MCF7 cells measured after 48 hrs by SRB assay
    		[PMID: 27671497]
    MCF7 IC50
    18.71 μM
    Compound: tamoxifen
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay
    		[PMID: 25734623]
    MCF7 IC50
    19 μM
    Compound: tamoxifen (TAM)
    Inhibition of 10e-4 uM estradiol induced estrogen receptor positive MCF-7 human breast cancer cell proliferation
    Inhibition of 10e-4 uM estradiol induced estrogen receptor positive MCF-7 human breast cancer cell proliferation
    		[PMID: 8784443]
    MCF7 IC50
    19.2 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay
    		[PMID: 33852304]
    MCF7 IC50
    19.33 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay
    		[PMID: 27311894]
    MCF7 IC50
    19.5 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 29482944]
    MCF7 IC50
    19.54 μM
    Compound: Tam
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
    		[PMID: 22647217]
    MCF7 IC50
    2.1 μM
    Compound: tamoxifen
    Antiproliferative activity against human MCF7 cells after 5 days by WST-8 assay
    Antiproliferative activity against human MCF7 cells after 5 days by WST-8 assay
    		[PMID: 25614118]
    MCF7 IC50
    2.3 μM
    Compound: Tamoxifen
    Antiproliferative activity in MCF-7 human breast cancer cells
    Antiproliferative activity in MCF-7 human breast cancer cells
    		[PMID: 15658875]
    MCF7 IC50
    2.33 μM
    Compound: 1
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
    		[PMID: 37019030]
    MCF7 IC50
    2.7 μM
    Compound: Tamoxifen
    Cytostatic activity against human MCF7 cells
    Cytostatic activity against human MCF7 cells
    		[PMID: 29207335]
    MCF7 IC50
    20 nM
    Compound: 7
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 33479633]
    MCF7 IC50
    20.24 μM
    Compound: Tmx
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 36481599]
    MCF7 IC50
    200 nM
    Compound: Tamoxifen
    Antagonist activity at ERalpha receptor in human MCF7 cells assessed as inhibition of cell growth after 6 days by crystal violet staining method
    Antagonist activity at ERalpha receptor in human MCF7 cells assessed as inhibition of cell growth after 6 days by crystal violet staining method
    		[PMID: 23448346]
    MCF7 IC50
    21.57 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    		[PMID: 28505536]
    MCF7 IC50
    219 nM
    Compound: TAM Z
    In vitro inhibition of MCF-7 cell proliferation compared to 0.1 nM [3H]-estradiol.
    In vitro inhibition of MCF-7 cell proliferation compared to 0.1 nM [3H]-estradiol.
    		[PMID: 2769681]
    MCF7 IC50
    22.47 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells
    Antiproliferative activity against human MCF7 cells
    		[PMID: 37875056]
    MCF7 IC50
    22.6 μM
    Compound: TAM
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31620225]
    MCF7 IC50
    25 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method
    Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method
    		[PMID: 31610378]
    MCF7 IC50
    25 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay
    Antiproliferative activity against human MCF7cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay
    		[PMID: 31673312]
    MCF7 IC50
    25 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 32386856]
    MCF7 IC50
    25.787 μM
    Compound: 1; TMX
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by CVDK-8 method
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by CVDK-8 method
    		[PMID: 37484572]
    MCF7 IC50
    27.96 μM
    Compound: 1, TAM
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 23860592]
    MCF7 IC50
    3.53 μM
    Compound: Tamoxifen
    Anticancer activity against human MCF7 cells
    Anticancer activity against human MCF7 cells
    		[PMID: 31926469]
    MCF7 IC50
    3.8 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay
    		[PMID: 26079090]
    MCF7 IC50
    3.99 μg/mL
    Compound: Tamoxifen
    Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay
    Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay
    		[PMID: 28442256]
    MCF7 IC50
    30 nM
    Compound: Tam
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
    		[PMID: 33257172]
    MCF7 IC50
    31 μM
    Compound: TEM
    Cytotoxicity activity against human MCF7 cells by MTS assay
    Cytotoxicity activity against human MCF7 cells by MTS assay
    		[PMID: 21680064]
    MCF7 IC50
    4 μM
    Compound: TAM
    Cytotoxicity against human MCF7 Cells after 48 hrs by neutral red dye-based assay
    Cytotoxicity against human MCF7 Cells after 48 hrs by neutral red dye-based assay
    		[PMID: 31129455]
    MCF7 IC50
    4.1 μM
    Compound: 2
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 25369367]
    MCF7 IC50
    4.1 μM
    Compound: 2a
    Antiproliferative activity against ER-dependent human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against ER-dependent human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 28426931]
    MCF7 IC50
    4.1 μM
    Compound: Tamoxifen
    Antiproliferative activity against ER-positive human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by AlamarBlue assay
    Antiproliferative activity against ER-positive human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by AlamarBlue assay
    		[PMID: 27407030]
    MCF7 IC50
    4.12 μM
    Compound: 1a
    Antiproliferative activity against estrogen receptor dependent human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against estrogen receptor dependent human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 18835176]
    MCF7 IC50
    4.12 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    		[PMID: 31987694]
    MCF7 IC50
    4.4 μM
    Compound: 2a
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by SRB assay
    		[PMID: 28426931]
    MCF7 IC50
    4.4 μM
    Compound: TAM
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 26896706]
    MCF7 IC50
    4.67 μM
    Compound: Tam
    Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay
    Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay
    		[PMID: 25222876]
    MCF7 IC50
    42.4 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 30731397]
    MCF7 IC50
    481 nM
    Compound: 1 (tamoxifen)
    Inhibition of estrogen-induced proliferation in human MCF-7 breast cancer cells
    Inhibition of estrogen-induced proliferation in human MCF-7 breast cancer cells
    		[PMID: 9154963]
    MCF7 IC50
    5.09 μM
    Compound: TAM
    Antiproliferative activity against MCF7 cells at 3 mg/kg/day after 48 hrs
    Antiproliferative activity against MCF7 cells at 3 mg/kg/day after 48 hrs
    		[PMID: 16979337]
    MCF7 IC50
    5.19 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    		[PMID: 23806014]
    MCF7 IC50
    5.3 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
    		[PMID: 27176944]
    MCF7 IC50
    5.3 μM
    Compound: Tamoxifen
    Growth inhibition of human MCF7 cells after 72 hrs by MTT assay
    Growth inhibition of human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 29220789]
    MCF7 IC50
    5.4 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 34726897]
    MCF7 IC50
    5.5 μM
    Compound: TAM
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 23287057]
    MCF7 IC50
    5.62 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 33894490]
    MCF7 IC50
    5.8 μM
    Compound: Tamoxifen
    Induction of apoptosis in human MCF7 cells in presence of EGCG at 50 uM
    Induction of apoptosis in human MCF7 cells in presence of EGCG at 50 uM
    		[PMID: 36780831]
    MCF7 IC50
    50 μM
    Compound: Tamoxifen
    Cytotoxicity against human ER-positive MCF7 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human ER-positive MCF7 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26972118]
    MCF7 IC50
    50 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 36846377]
    MCF7 IC50
    50 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay
    		[PMID: 36846377]
    MCF7 IC50
    54 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 33234343]
    MCF7 IC50
    55.5 μM
    Compound: Tamoxifen
    Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
    		10.1007/s00044-012-0391-5
    MCF7 IC50
    580 nM
    Compound: 3 (Tamoxifen)
    Inhibitory concentration against MCF-7 breast tumor cells using MCF-7 assay.
    Inhibitory concentration against MCF-7 breast tumor cells using MCF-7 assay.
    		[PMID: 12825935]
    MCF7 IC50
    580 nM
    Compound: tamoxifen
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTS assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTS assay
    		[PMID: 18272256]
    MCF7 IC50
    6 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 24880230]
    MCF7 IC50
    6.3 μM
    Compound: Tamoxifen
    Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
    Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
    		[PMID: 33373820]
    MCF7 IC50
    6.99 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    		[PMID: 27228159]
    MCF7 IC50
    64.3 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 25164760]
    MCF7 IC50
    7.09 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 30360952]
    MCF7 IC50
    7.1 μM
    Compound: 2
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    		[PMID: 22749392]
    MCF7 IC50
    7.65 μM
    Compound: TAM
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 19740667]
    MCF7 IC50
    7.94 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay
    Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay
    		[PMID: 28927795]
    MCF7 IC50
    70 nM
    Compound: Tamoxifen
    Inhibition of estrogen receptor positive MCF-7 breast cancer cell proliferation
    Inhibition of estrogen receptor positive MCF-7 breast cancer cell proliferation
    		[PMID: 14971899]
    MCF7 IC50
    8 μM
    Compound: Tam Z
    Cytostaticity against MCF-7 cells in the presence of 1 uMolar E2 (estradiol)
    Cytostaticity against MCF-7 cells in the presence of 1 uMolar E2 (estradiol)
    		[PMID: 9089332]
    MCF7 IC50
    8.12 μM
    Compound: TAM
    Antiproliferative activity against estrogen receptor positive human MCF7 cells assessed as inhibition of cell viability by MTT assay
    Antiproliferative activity against estrogen receptor positive human MCF7 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 38729318]
    MCF7 IC50
    8.12 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 29054359]
    MCF7 IC50
    8.31 μg/mL
    Compound: TAM
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 21115211]
    MCF7 IC50
    8.38 μg/mL
    Compound: Tamoxifen
    Anticancer activity against human MCF7 cells assessed a cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human MCF7 cells assessed a cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 32771798]
    MCF7 IC50
    8.42 μM
    Compound: TAM
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 34153643]
    MCF7 IC50
    8.53 μM
    Compound: 1
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 35276362]
    MCF7 IC50
    8.5 μg/mL
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    		[PMID: 36325400]
    MCF7 IC50
    8.6 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay in presence of 20% FBS
    Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay in presence of 20% FBS
    		[PMID: 22901895]
    MCF7 IC50
    8.61 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
    		[PMID: 29605808]
    MCF7 IC50
    8.9 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 20605470]
    MCF7 IC50
    82.5 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 25164760]
    MCF7 IC50
    8 μg/mL
    Compound: Tamoxifen
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 24576797]
    MCF7 IC50
    9 μM
    Compound: TAM
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 24457094]
    MCF7 IC50
    9 μM
    Compound: Tamoxifen
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 32731188]
    MCF7 IC50
    9.6 μM
    Compound: Tamoxifen
    Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33373820]
    MCF7 IC50
    < 1000 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    		[PMID: 36603398]
    MCF7S IC50
    7200 nM
    Compound: 1a
    Inhibition of [3H]thymidine incorporation into MCF-7 cells
    Inhibition of [3H]thymidine incorporation into MCF-7 cells
    		[PMID: 1573630]
    MDA-MB-231 ED50
    8.5 μg/mL
    Compound: TAM
    Cytotoxicity against human MDA-MB-231 cells lacking ER
    Cytotoxicity against human MDA-MB-231 cells lacking ER
    		[PMID: 16942038]
    MDA-MB-231 GI50
    0.12 μM
    Compound: Tamoxifen
    Growth inhibition of human MDA-MB-231 cells
    Growth inhibition of human MDA-MB-231 cells
    		[PMID: 31605865]
    MDA-MB-231 GI50
    0.24 μM
    Compound: Tamoxifen
    Cytotoxicity against human MDA-MB-231 cells
    Cytotoxicity against human MDA-MB-231 cells
    		[PMID: 31200236]
    MDA-MB-231 GI50
    0.24 μM
    Compound: Tamoxifen
    Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by SRB assay
    Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by SRB assay
    		[PMID: 36577217]
    MDA-MB-231 GI50
    0.24 μM
    Compound: Tamoxifen
    Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by SRB assay
    Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by SRB assay
    		[PMID: 38911170]
    MDA-MB-231 GI50
    15.1 μM
    Compound: Tamoxifen
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 120 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 120 hrs by MTT assay
    		[PMID: 28152429]
    MDA-MB-231 GI50
    18.8 μM
    Compound: Tamoxifen
    Growth inhibition of estrogen-independent human MDA-MB-231 cells
    Growth inhibition of estrogen-independent human MDA-MB-231 cells
    		[PMID: 23403084]
    MDA-MB-231 IC50
    0.66 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    		[PMID: 20451380]
    MDA-MB-231 IC50
    10 μM
    Compound: TAM
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 24457094]
    MDA-MB-231 IC50
    10 μM
    Compound: Tamoxifen
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 20605470]
    MDA-MB-231 IC50
    10.11 μM
    Compound: TAM
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 34153643]
    MDA-MB-231 IC50
    11.2 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    		[PMID: 31546197]
    MDA-MB-231 IC50
    11.4 μM
    Compound: TAM
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 23287057]
    MDA-MB-231 IC50
    12.4 μM
    Compound: Tamoxifen
    Cytotoxicity against human MDA-MB-231 cells by WST-1 assay
    Cytotoxicity against human MDA-MB-231 cells by WST-1 assay
    		[PMID: 19836230]
    MDA-MB-231 IC50
    12.41 μM
    Compound: Tamoxifen
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 23022281]
    MDA-MB-231 IC50
    13.9 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
    		[PMID: 27176944]
    MDA-MB-231 IC50
    14 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 24880230]
    MDA-MB-231 IC50
    14.5 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MDA-MB-231 cells by MTT reduction assay
    Antiproliferative activity against human MDA-MB-231 cells by MTT reduction assay
    		[PMID: 33421712]
    MDA-MB-231 IC50
    14.94 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 35276362]
    MDA-MB-231 IC50
    15.01 μM
    Compound: Tamoxifen
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 33894490]
    MDA-MB-231 IC50
    17 μM
    Compound: Tamoxifen
    Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23786452]
    MDA-MB-231 IC50
    17.9 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MDA-MB-231 cells
    Antiproliferative activity against human MDA-MB-231 cells
    		[PMID: 27155469]
    MDA-MB-231 IC50
    18.08 μM
    Compound: Tamoxifen
    Binding affinity to rRNA-A site in human MDA-MB-231 cells assessed as inhibition of protein translation
    Binding affinity to rRNA-A site in human MDA-MB-231 cells assessed as inhibition of protein translation
    		[PMID: 30530174]
    MDA-MB-231 IC50
    18.48 μM
    Compound: Tamoxifen
    Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay
    Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay
    		[PMID: 37146520]
    MDA-MB-231 IC50
    18.9 μM
    Compound: Tamoxifen
    Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells expressing estrogen receptor after 48 hrs by MTT assay
    Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells expressing estrogen receptor after 48 hrs by MTT assay
    		[PMID: 21871812]
    MDA-MB-231 IC50
    19 μM
    Compound: Tamoxifen
    Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay
    Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay
    		[PMID: 12565971]
    MDA-MB-231 IC50
    20 μM
    Compound: tamoxifene
    Antiproliferative activity against human estrogen receptor deficient MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human estrogen receptor deficient MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 19423356]
    MDA-MB-231 IC50
    24 μM
    Compound: tamoxifen
    Anticancer activity against estrogen-positive human MDA-MB-231 cells after 18 hrs by MTT assay
    Anticancer activity against estrogen-positive human MDA-MB-231 cells after 18 hrs by MTT assay
    		[PMID: 19446930]
    MDA-MB-231 IC50
    25 μM
    Compound: 1; TMX
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth
    		[PMID: 37484572]
    MDA-MB-231 IC50
    25.1 μM
    Compound: Tamoxifen
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
    		10.1007/s00044-012-0391-5
    MDA-MB-231 IC50
    25.575 μM
    Compound: 1; TMX
    Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CVDK-8 method
    Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CVDK-8 method
    		[PMID: 37484572]
    MDA-MB-231 IC50
    25.9 μM
    Compound: TMX
    Cytotoxicity against human MDA-MB-231 assessed as reduction in cell viability measured after 48 hrs by WST-1 assay
    Cytotoxicity against human MDA-MB-231 assessed as reduction in cell viability measured after 48 hrs by WST-1 assay
    		[PMID: 38020071]
    MDA-MB-231 IC50
    27 μM
    Compound: Tam
    Cytotoxicity against human ER negative MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human ER negative MDA-MB-231 cells after 48 hrs by MTT assay
    		10.1039/C4MD00289J
    MDA-MB-231 IC50
    28 μM
    Compound: Tamoxifen
    In vitro inhibition of estrogen receptor negative MDA-MD-231 human mammary carcinoma cell proliferation
    In vitro inhibition of estrogen receptor negative MDA-MD-231 human mammary carcinoma cell proliferation
    		10.1016/0960-894X(95)00381-3
    MDA-MB-231 IC50
    30.848 μM
    Compound: 1; TMX
    Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by CVDK-8 method
    Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by CVDK-8 method
    		[PMID: 37484572]
    MDA-MB-231 IC50
    35.8 μM
    Compound: Tamoxifen
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 33340662]
    MDA-MB-231 IC50
    38.97 μM
    Compound: Tam
    Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay
    Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay
    		[PMID: 25222876]
    MDA-MB-231 IC50
    47.1 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 30360952]
    MDA-MB-231 IC50
    5.9 μM
    Compound: Tamoxifen
    Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
    Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
    		[PMID: 33373820]
    MDA-MB-231 IC50
    64.85 μM
    Compound: 1, TAM
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 23860592]
    MDA-MB-231 IC50
    69.7 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    		[PMID: 33139111]
    MDA-MB-231 IC50
    7 μM
    Compound: Tamoxifen
    Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33373820]
    MDA-MB-231 IC50
    7.85 μg/mL
    Compound: Tamoxifen
    Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay
    Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay
    		[PMID: 28442256]
    MDA-MB-231 IC50
    75 μM
    Compound: Tamoxifen
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 25164760]
    MDA-MB-231 IC50
    75 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 33234343]
    MDA-MB-231 IC50
    80 nM
    Compound: Tamoxifen
    Inhibition of estrogen receptor negative MDA-MB-231 breast cancer cell proliferation
    Inhibition of estrogen receptor negative MDA-MB-231 breast cancer cell proliferation
    		[PMID: 14971899]
    MDA-MB-231 IC50
    84.6 μM
    Compound: Tamoxifen
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 25164760]
    MDA-MB-231 IC50
    9.86 μM
    Compound: TAM
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 19740667]
    MDA-MB-231 IC50
    9.96 μM
    Compound: TAM
    Antiproliferative activity against estrogen receptor negative human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay
    Antiproliferative activity against estrogen receptor negative human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 38729318]
    MDA-MB-231 IC50
    9.96 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 29054359]
    MDA-MB-231 IC50
    < 1000 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    		[PMID: 36603398]
    MDA-MB-231 IC50
    > 20 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    		[PMID: 31884407]
    MDA-MB-231 IC50
    > 50 μM
    Compound: Tamoxifen
    Cytotoxicity against human ER-negative MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human ER-negative MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26972118]
    MDA-MB-231 IC50
    > 50 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 34022716]
    MDA-MB-435 GI50
    3.16 μM
    Compound: TAM
    Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26896706]
    MDA-MB-435 IC50
    0.1 μM
    Compound: Tamoxifen
    Antiproliferative activity against human MDA-MB-435 cells
    Antiproliferative activity against human MDA-MB-435 cells
    		[PMID: 33421712]
    MDA-MB-435 IC50
    50 nM
    Compound: Tamoxifen
    Inhibition of MDA-MB-435 breast cancer cell proliferation
    Inhibition of MDA-MB-435 breast cancer cell proliferation
    		[PMID: 14971899]
    MDA-MB-435S IC50
    5.5 μM
    Compound: Tamoxifen
    Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay
    Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay
    		[PMID: 26079090]
    MDA-MB-436 IC50
    15.8 μM
    Compound: TMX
    Cytotoxicity against human MDA-MB-436 assessed as reduction in cell viability measured after 48 hrs by WST-1 assay
    Cytotoxicity against human MDA-MB-436 assessed as reduction in cell viability measured after 48 hrs by WST-1 assay
    		[PMID: 38020071]
    MDA-MB-453 IC50
    > 5 μM
    Compound: tamoxifen (TAM)
    Inhibition of estrogen receptor negative MDA-MB-453 breast cancer cell proliferation with 10e-4 M estradiol
    Inhibition of estrogen receptor negative MDA-MB-453 breast cancer cell proliferation with 10e-4 M estradiol
    		[PMID: 8784443]
    MDA-MB-468 GI50
    2.5 μM
    Compound: TAM
    Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26896706]
    MDA-MB-468 IC50
    14.99 μM
    Compound: Tam
    Cytotoxicity against human ER negative MDA-MB-468 cells after 48 hrs by MTT assay
    Cytotoxicity against human ER negative MDA-MB-468 cells after 48 hrs by MTT assay
    		10.1039/C4MD00289J
    MEL-JUSO EC50
    14.6 μM
    Compound: TAM
    Antiproliferative activity against human MelJuSo cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay
    Antiproliferative activity against human MelJuSo cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay
    		[PMID: 31099568]
    MIA PaCa-2 IC50
    33.12 μM
    Compound: Tam
    Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay
    Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay
    		[PMID: 25222876]
    MOLT-4 GI50
    2.5 μM
    Compound: TAM
    Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26896706]
    MRC5 CC50
    10 μM
    Compound: Tamoxifen
    Cytotoxicity against human MRC5 cells measured after 7 days by MTT assay
    Cytotoxicity against human MRC5 cells measured after 7 days by MTT assay
    		[PMID: 33667089]
    MRC5 CC50
    11.09 μM
    Compound: Tamoxifen
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by resazurin dye based fluorimetric assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by resazurin dye based fluorimetric assay
    		[PMID: 30857749]
    MRC5 IC50
    10.9 μM
    Compound: TAM
    Cytotoxicity against human MRC5 cells assessed as cell viability after 4 to 7 days by Alamar Blue staining based fluorometric analysis
    Cytotoxicity against human MRC5 cells assessed as cell viability after 4 to 7 days by Alamar Blue staining based fluorometric analysis
    		[PMID: 26922226]
    MRC5 IC50
    11.09 μM
    Compound: Tamoxifen
    Cytotoxicity against human MRC5 cells after 24 hrs by resazurin dye based assay
    Cytotoxicity against human MRC5 cells after 24 hrs by resazurin dye based assay
    		[PMID: 30692024]
    MRC5 IC50
    11.09 μM
    Compound: Tamoxifen
    Cytotoxicity in human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay
    Cytotoxicity in human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay
    		[PMID: 30879839]
    MRC5 IC50
    17.2 μM
    Compound: Tamoxifen
    Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis
    Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis
    		[PMID: 36242986]
    MSTO-211H GI50
    23.3 μM
    Compound: 1
    Antiproliferative activity against human MSTO-211H cells after 72 hrs by trypan blue assay
    Antiproliferative activity against human MSTO-211H cells after 72 hrs by trypan blue assay
    		[PMID: 23735829]
    MVLN IC50
    0.3 μM
    Compound: Tam Z
    Anti-estrogenicity for 50% inhibition of the MVLN cell luciferase activity due to 0.1 nM E2 (estradiol)
    Anti-estrogenicity for 50% inhibition of the MVLN cell luciferase activity due to 0.1 nM E2 (estradiol)
    		[PMID: 9089332]
    NCI-H460 GI50
    4.48 μM
    Compound: Tamoxifen
    Anticancer activity against human NCI-H460 cells after 24 hrs by SRB assay
    Anticancer activity against human NCI-H460 cells after 24 hrs by SRB assay
    		[PMID: 19733085]
    NCI/ADR-RES IC50
    11.13 μM
    Compound: Tamoxifen
    Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 23022281]
    NCI/ADR-RES IC50
    2000 nM
    Compound: Tamoxifen
    Inhibition of MCF-7/Adr breast cancer cell proliferation
    Inhibition of MCF-7/Adr breast cancer cell proliferation
    		[PMID: 14971899]
    NIH-3T3-G185 IC50
    12.1 μM
    Compound: Tamoxifen
    TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells
    TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells
    		[PMID: 11716514]
    NIH-3T3-G185 IC50
    31.4 μM
    Compound: Tamoxifen
    TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells
    TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells
    		[PMID: 11716514]
    NIH-3T3-G185 IC50
    6.4 μM
    Compound: Tamoxifen
    TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells
    TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells
    		[PMID: 11716514]
    NIH3T3 IC50
    10.66 μg/mL
    Compound: Tamoxifen
    Phototoxicity against BALB/c mouse 3T3 cells assessed as reduction in cell viability preincubated for 1 hr followed by 5 J/cm2 irradiation and subsequent replacement of medium without compound and measured after 24 hrs by neutral red dye based assay
    Phototoxicity against BALB/c mouse 3T3 cells assessed as reduction in cell viability preincubated for 1 hr followed by 5 J/cm2 irradiation and subsequent replacement of medium without compound and measured after 24 hrs by neutral red dye based assay
    		[PMID: 38128906]
    NIH3T3 IC50
    11.4 μM
    Compound: TAM
    Antiproliferative activity against mouse NIH/3T3 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse NIH/3T3 cells after 48 hrs by MTT assay
    		[PMID: 23287057]
    NIH3T3 IC50
    13.03 μg/mL
    Compound: Tamoxifen
    Dark toxicity against BALB/c mouse 3T3 cells assessed as reduction in cell viability incubated for 1 hr by neutral red dye based assay
    Dark toxicity against BALB/c mouse 3T3 cells assessed as reduction in cell viability incubated for 1 hr by neutral red dye based assay
    		[PMID: 38128906]
    NIH3T3 IC50
    7.26 μM
    Compound: 2
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    		[PMID: 22749392]
    NIH3T3 IC50
    > 100 μM
    Compound: Tam
    Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay
    Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay
    		[PMID: 25222876]
    OVCAR-5 GI50
    32 μM
    Compound: 1
    Cytotoxicity against human OVCAR5 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    Cytotoxicity against human OVCAR5 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    		[PMID: 27128175]
    PANC-1 GI50
    0.12 μM
    Compound: Tamoxifen
    Growth inhibition of human PANC1 cells
    Growth inhibition of human PANC1 cells
    		[PMID: 31605865]
    PANC-1 GI50
    0.15 μM
    Compound: Tamoxifen
    Cytotoxicity against human PANC1 cells
    Cytotoxicity against human PANC1 cells
    		[PMID: 31200236]
    PC-3 IC50
    10 μM
    Compound: TAM
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 23287057]
    PC-3 IC50
    15.8 μM
    Compound: TAM
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 34153643]
    PC-3 IC50
    7 μM
    Compound: Tamoxifen
    Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay
    		[PMID: 24880230]
    PC-3 IC50
    > 1000 nM
    Compound: 7
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 33479633]
    PC-3 IC50
    > 40 μM
    Compound: Tamoxifen
    Antiproliferative activity against human PC3 cells
    Antiproliferative activity against human PC3 cells
    		[PMID: 27155469]
    RAW264.7 CC50
    11.1 μM
    Compound: Tamoxifen
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by neutral red dye based assay
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by neutral red dye based assay
    		[PMID: 31703818]
    RAW264.7 CC50
    5.03 μM
    Compound: Tamoxifen
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction of cell viability incubated for 72 hrs by Cell Titer-Glo assay
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction of cell viability incubated for 72 hrs by Cell Titer-Glo assay
    		[PMID: 37871508]
    RAW264.7 IC50
    18.5 μM
    Compound: Tamoxifen
    Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis
    Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis
    		[PMID: 36242986]
    SH-SY5Y IC50
    20 μM
    Compound: Tamoxifen
    Inhibition of PKC in human SH-SY5Y cells assessed as inhibition of PMA-stimulated MARCKS phosphorylation preincubated for 1 hr followed by PMA-stimulation for 15 mins by Western blot analysis
    Inhibition of PKC in human SH-SY5Y cells assessed as inhibition of PMA-stimulated MARCKS phosphorylation preincubated for 1 hr followed by PMA-stimulation for 15 mins by Western blot analysis
    		[PMID: 27647375]
    SK-BR-3 ED50
    5 μg/mL
    Compound: TAM
    Cytotoxicity against human SK-BR-3 cells expressing HER2 and lacking ER
    Cytotoxicity against human SK-BR-3 cells expressing HER2 and lacking ER
    		[PMID: 16942038]
    SK-BR-3 ED50
    5 μg/mL
    Compound: TAM
    Cytotoxicity against estrogen receptor deficient human SKBR3 cells overexpressing human epidermal growth factor receptor 2 after 72 hrs by SRB assay
    Cytotoxicity against estrogen receptor deficient human SKBR3 cells overexpressing human epidermal growth factor receptor 2 after 72 hrs by SRB assay
    		[PMID: 19425534]
    SK-BR-3 GI50
    12.5 μM
    Compound: Tamoxifen
    Cytotoxicity against human SKBR3 cells assessed as growth inhibition after 120 hrs by MTT assay
    Cytotoxicity against human SKBR3 cells assessed as growth inhibition after 120 hrs by MTT assay
    		[PMID: 28152429]
    SK-BR-3 IC50
    28.32 μM
    Compound: Tamoxifen
    Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay
    Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay
    		[PMID: 33340662]
    SK-BR-3 IC50
    < 1000 μM
    Compound: Tamoxifen
    Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    		[PMID: 36603398]
    SK-MEL-28 IC50
    1.86 μg/mL
    Compound: Tomoxifen
    Cytotoxicity against human SK-MEL-28 cells by alamar blue assay
    Cytotoxicity against human SK-MEL-28 cells by alamar blue assay
    		[PMID: 11720540]
    SK-OV-3 GI50
    10 μM
    Compound: TAM
    Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26896706]
    SK-OV-3 GI50
    6.4 μM
    Compound: Tamoxifen
    Anticancer activity against human SKOV3 cells after 24 hrs by SRB assay
    Anticancer activity against human SKOV3 cells after 24 hrs by SRB assay
    		[PMID: 19733085]
    SNB-75 GI50
    5.01 μM
    Compound: TAM
    Cytotoxicity against human SNB75 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human SNB75 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26896706]
    SW-620 ED50
    4 μg/mL
    Compound: TAM
    Cytotoxicity against human SW620 cells
    Cytotoxicity against human SW620 cells
    		[PMID: 16942038]
    SiHa GI50
    0.12 μM
    Compound: Tamoxifen
    Cytotoxicity against human SiHa cells
    Cytotoxicity against human SiHa cells
    		[PMID: 31200236]
    SiHa GI50
    0.12 μM
    Compound: Tamoxifen
    Growth inhibition of human SiHa cells
    Growth inhibition of human SiHa cells
    		[PMID: 31605865]
    SiHa GI50
    0.12 μM
    Compound: Tamoxifen
    Growth inhibition of human SiHa cells measured after 48 hrs by SRB assay
    Growth inhibition of human SiHa cells measured after 48 hrs by SRB assay
    		[PMID: 36577217]
    T47D GI50
    1.99 μM
    Compound: TAM
    Cytotoxicity against human T47D cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human T47D cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26896706]
    T47D GI50
    10.6 μM
    Compound: Tamoxifen
    Cytotoxicity against human T47D cells assessed as growth inhibition after 120 hrs by MTT assay
    Cytotoxicity against human T47D cells assessed as growth inhibition after 120 hrs by MTT assay
    		[PMID: 28152429]
    T47D IC50
    0.1 μM
    Compound: Tamoxifen
    Antiestrogenic activity in human T47D cells expressing estrogen receptor assessed as estrogen-dependent transcription by luciferase reporter gene assay
    Antiestrogenic activity in human T47D cells expressing estrogen receptor assessed as estrogen-dependent transcription by luciferase reporter gene assay
    		[PMID: 19131248]
    T47D IC50
    1 μM
    Compound: Tamoxifen
    Growth inhibition of human estrogen-dependent T47D cells after 72 hrs
    Growth inhibition of human estrogen-dependent T47D cells after 72 hrs
    		[PMID: 19131248]
    T47D IC50
    1.13 μM
    Compound: Tamoxifen
    Cytotoxicity against human T47D cells after 5 days
    Cytotoxicity against human T47D cells after 5 days
    		[PMID: 23864928]
    T47D IC50
    12.1 μM
    Compound: Tamoxifen
    Cytotoxicity against Homo sapiens (human) T47D cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) T47D cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
    		10.1007/s00044-012-0391-5
    T47D IC50
    13 μM
    Compound: TAM
    Antiproliferative activity against human T47D cells after 48 hrs by MTT assay
    Antiproliferative activity against human T47D cells after 48 hrs by MTT assay
    		[PMID: 23287057]
    T47D IC50
    14.2 μM
    Compound: Tamoxifen
    Antiproliferative activity against human T47D cells by MTT reduction assay
    Antiproliferative activity against human T47D cells by MTT reduction assay
    		[PMID: 33421712]
    T47D IC50
    29.9 μM
    Compound: Tam
    Cytotoxicity against human T47D cells expressing ER after 48 hrs by MTT assay
    Cytotoxicity against human T47D cells expressing ER after 48 hrs by MTT assay
    		10.1039/C4MD00289J
    T47D IC50
    34.42 μM
    Compound: Tamoxifen
    Antiproliferative activity against human T47D cells after 24 hrs by MTT assay
    Antiproliferative activity against human T47D cells after 24 hrs by MTT assay
    		[PMID: 30731397]
    THP-1 IC50
    11.91 μM
    Compound: Tamoxifen
    Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    		[PMID: 31884407]
    UO-31 GI50
    6.3 μM
    Compound: TAM
    Cytotoxicity against human UO31 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human UO31 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26896706]
    Vero IC50
    15.9 μM
    Compound: Tamoxifen
    Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23786452]
    Vero IC50
    36.2 μM
    Compound: Tamoxifen
    Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay
    Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay
    		[PMID: 37146520]
    Vero IC50
    5.7 μM
    Compound: Tamoxifen
    Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay
    Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay
    		[PMID: 26079090]
    ZR-75-1 ED50
    3.6 μg/mL
    Compound: TAM
    Cytotoxicity against human ZR-75-1 cells expressing ER
    Cytotoxicity against human ZR-75-1 cells expressing ER
    		[PMID: 16942038]
    体外研究
    (In Vitro)

    Tamoxifen (ICI 47699) 对 MCF-7 细胞 (EC50=1.41 μM) 表现出强烈的抑制作用，对 T47D 细胞 (EC50=2.5 μM) 的抑制作用较小，但不影响 MDA-MB-231 细胞[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Tamoxifen 相关抗体:
    体内研究
    (In Vivo)

    注意：
    请勿仅参考一篇文章来确定实验条件。建议在正式实验前，通过预实验确定最佳实验条件 (动物品系、年龄、剂量、频率及周期、检测时间及指标等)。

    Tamoxifen 诱导基因敲除策略具有明显的优势，即可以按照需要在成年小鼠中以组织特异性的方式消除特定基因的表达。为了研究 Med1 在成年心脏中的作用，7 周龄的 TmcsMed1-/- 小鼠每天接受一次剂量为 65 mg/kg (Tamoxifen Citrate) 的 Tamoxifen 腹腔注射，连续注射 5 天，并在选定的时间间隔后处死。RNA 的 qPCR 分析显示，注射 Tamoxifen 3 天后 Med1 表达开始减少（约减少 70%），而在注射 5 天后，心脏中的 Med1 表达几乎检测不到。在成年小鼠中，通过 Tamoxifen 诱导的心脏特异性 Med1 基因敲除（TmcsMed1-/-）会导致扩张型心肌病[3]。

    1. 诱导基因敲除模型[8][9]
    致病原理
    Tamoxifen 诱导基因敲除使用的是 Cre-Loxp 小鼠，其 Cre 重组酶是由组织/细胞特异性 Promoter 驱动，并且靶基因两侧带有 Loxp 位点。将 Cre 重组酶与雌激素受体的配体结合域融合，构建 Cre-ER 融合蛋白，通过 Tamoxifen 诱导 Cre 的重组活性。在没有 Tamoxifen 的情况下，Cre-ER 融合蛋白与 HSP90 结合，存在于细胞质中。当 Tamoxifen 诱导后，Tamoxifen 代谢产物 4-OHT 会与 Cre-ER 蛋白结合，激活 Cre 重组酶并进入细胞核中，识别 Loxp 位点，介绍两个同向 Loxp 位点之间的基因敲除。(为了避免内源性雌激素的干扰，会对雌激素受体的配体结合区进行改造，将 Cre-ER 变为 MerCreMer、Cre-ERT 或 Cre-ERT2)。
    具体造模方法
    Mice: Cx3cr1CreERT/+: Pdgfbfl/fl (Conditional knockout of Pdgfb in microglia)
    Administration: 75 mg/kg • i.p. • 5 consecutive days
    Note
    请勿直接参照一篇文献确定实验条件，建议在正式实验前查阅数篇文献，并通过预实验确定最佳实验条件 (动物品系、周龄、给药剂量、频率与周期、检测时间与指标等)

    (1) 溶解：Tamoxifen 难溶于水，文献中常用玉米油 (HY-Y1888) 溶解，可通过 37℃ 加热或超声助溶，确保溶清。Tamoxifen 需避光配制，建议现配现用。玉米油较为粘稠，在吸取溶液时可以不插上针头，吸取溶液后再装上针头并驱赶气泡。
    (2) 给药方式：常见腹腔注射，也可口服灌胃、皮下注射等。多次腹腔注射时，应交替注射部位。
    (3) 建议给药剂量：50-120 mg/kg， 腹腔注射 3-5 次，多为连续 5 天腹腔注射，孕鼠及老龄鼠 (大于 6 月龄) 的剂量需适当减少。Tamoxifen 会影响胎儿发育和生产，孕鼠诱导的时间尽量选择孕晚期，并同时注射孕酮来减少流产概率。
    (4) 鼠：4-6 周龄小鼠可能更敏感 (年轻小鼠中比在年老小鼠中更有效)。
    (5) 潜在毒性：长时间高水平的 Cre 活性会导致潜在的毒性，此外，如果敲的是重要的功能基因，或者选用的是纯合子小鼠，也可能会导致小鼠死亡；所以要在诱导后的一两周内密切观察，若小鼠异常，需要及时分析原因，调整实验方案。
    (6) 如何做对照：对照组小鼠需注射等量 Tamoxifen 玉米油溶液 (在没有 Cre 重组酶的遗传背景下使用 Tamoxifen)，排除 Tamoxifen 本身的影响。
    (7) 检测窗口：Tamoxifen 给药和实验开始之间的时间窗口应足够大，至少 7 天。确保 Cre 重组酶进入细胞核并发挥作用。
    (8) 分笼：接受 Tamoxifen 处理的动物应与未处理的动物分笼饲养，避免由于动物舔油性他莫昔芬悬浮液、梳理毛发或食粪等行为导致的交叉污染。
    造模成功指标
    通过分子生物学和遗传学方法 (如 WB、PCR 和测序等) 在 RNA 或蛋白水平验证目的基因表达降低/敲除。
    同类产品： 4-Hydroxytamoxifen (HY-16950)
    拮抗产品：/
    2. 诱导肝损伤模型[10] [11]
    致病原理
    Tamoxifen 会降低己糖单磷酸旁路，从而增加大鼠肝细胞中氧化应激的发生率，导致肝脏损伤。
    具体造模方法：
    大鼠：白化病大鼠 • 雌性 • 处理 7 天
    给药方式：45 mg/kg • 腹腔注射 • 每天一次，连续 7 天
    Note
    (1) 大鼠处于标准的实验室环境下，即 12 小时光照/12 小时黑暗循环，温度保持在 25 ± 2°C，且可以自由获取食物和水。
    (2) 实验结束后，动物在轻度乙醚麻醉下通过颈椎脱位处死。将血液样本收集在肝素化的离心管中，离心得到血清。剖开腹部，立即解剖取出肝脏，用冰冷的等渗盐水洗涤，并在两张滤纸之间吸干。肝脏用铝箔包裹，在 -80℃ 下保存。使用超声仪在冰冷的 0.1 M 磷酸钾缓冲液（PH 7.5）中制备 10%（w/v）的肝匀浆。
    造模成功指标
    分子变化：抗氧化酶 (谷胱甘肽 S 转移酶、谷胱甘肽过氧化物酶和过氧化氢酶) 活性显著 ↓，还原型谷胱甘肽含量 ↓，同时硫代巴比妥酸反应物质 (TBARS) 和肝脏转氨酶(血清谷丙转氨酶 sGPT 和血清谷草转氨酶 sGOT) 水平显著 ↑。
    相关产品: /
    拮抗产品: /

    在大鼠中的药代动力学分析[12]
    Route Dose (mg/kg) AUC0-∞ (ng/mL·h) Cmax (ng/mL) Tmax (h) t1/2 (h) Absolute bioavailability (%) Relative bioavailability (%)
    p.o. 10 2060 126 1.17 11.2 22.2 100
    i.v. 2 1860 / / 9.0 100 /

    在小鼠中的药代动力学分析[13]
    Route Dose (mg/kg) Cmax (ng/mL) Tmax (h) Half-life (h) AUC0-∞ (ng/mL·h)
    p.o. 4 1.7 1.0 1.0 3.8
    p.o. 10 11.4 0.5 2.0 25.1
    p.o. 20 40.8 1.0 7.6 104
    s.c. 4 20.5 2.0 7.7 152
    s.c. 10 43.4 1.0 6.8 363
    s.c. 20 49.4 4.0 11.2 769

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Aldh1l1-cre/ERT2 x Ai95 mice[3]
    Dosage: 75 mg/kg
    Administration: Injected for 5 days at 6 weeks of age
    Result: Resulted in the excision of the floxed exon and a gene knockout.
    Clinical Trial
    分子量

    371.51

    Formula

    C26H29NO
    CAS 号
    性状

    固体

    颜色

    White to off-white

    中文名称

    他莫昔芬；三苯氧胺；它莫西芬
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    溶解性数据
    细胞实验： 

    Ethanol 中的溶解度 : 50 mg/mL (134.59 mM; 超声助溶)

    DMSO 中的溶解度 : 13.46 mg/mL (36.23 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.6917 mL 13.4586 mL 26.9172 mL
    5 mM 0.5383 mL 2.6917 mL 5.3834 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验：

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
    ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂： 10% DMSO    90% Corn Oil

      Solubility: ≥ 1.39 mg/mL (3.74 mM); 澄清溶液

      此方案可获得 ≥ 1.39 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。

      以 1 mL 工作液为例，取 100 μL 13.9 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

    以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比； 如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

    • 方案 一

      请依序添加每种溶剂： Corn Oil

      Solubility: 20 mg/mL (53.83 mM); 澄清溶液; 超声助溶

    动物溶解方案计算器
    请输入动物实验的基本信息：

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    只
    由于实验过程有损耗，建议您多配一只动物的量
    请输入您的动物体内配方组成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括：DMSO， ，均可在 MCE 网站选购。 ，Tween 80，均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO（母液浓度为 mg/mL）。

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。
    连续给药周期超过半月以上，请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 99.96%

    COA (286 KB) HNMR (267 KB) RP-HPLC (244 KB) LCMS (103 KB)

    产品使用指南 (1538 KB)
    参考文献

    Tamoxifen 相关分类

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO / Ethanol 1 mM 2.6917 mL 13.4586 mL 26.9172 mL 67.2929 mL
    5 mM 0.5383 mL 2.6917 mL 5.3834 mL 13.4586 mL
    10 mM 0.2692 mL 1.3459 mL 2.6917 mL 6.7293 mL
    15 mM 0.1794 mL 0.8972 mL 1.7945 mL 4.4862 mL
    20 mM 0.1346 mL 0.6729 mL 1.3459 mL 3.3646 mL
    25 mM 0.1077 mL 0.5383 mL 1.0767 mL 2.6917 mL
    30 mM 0.0897 mL 0.4486 mL 0.8972 mL 2.2431 mL
    Ethanol 40 mM 0.0673 mL 0.3365 mL 0.6729 mL 1.6823 mL
    50 mM 0.0538 mL 0.2692 mL 0.5383 mL 1.3459 mL
    60 mM 0.0449 mL 0.2243 mL 0.4486 mL 1.1215 mL
    80 mM 0.0336 mL 0.1682 mL 0.3365 mL 0.8412 mL
    100 mM 0.0269 mL 0.1346 mL 0.2692 mL 0.6729 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Tamoxifen10540-29-1ICI 47699(Z)-Tamoxifen trans-Tamoxifen他莫昔芬三苯氧胺它莫西芬ICI47699ICI-47699Estrogen Receptor/ERRHSPAutophagyApoptosisHeat shock proteinsestrogenmodulatorSERMbreastboneliveruterineHsp90chaperoneATPaseInhibitorinhibitorinhibit

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * 需求量：

    * 客户姓名：

    		 

    * Email：

    * 电话：

    		 

    * 公司或机构名称：

       留言给我们：

    Bulk Inquiry

    Inquiry Information

    产品名称：
    Tamoxifen
    目录号：
    HY-13757A
    需求量：

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * Lot #：

    * 客户姓名：

    		 

    * Email：

       电话：

    		 

    * 部门：

    * 公司或机构名称：

    		 

       留言给我们：

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.

    嗨！很高兴为您提供帮助！

    尊敬的 MCE 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z